Atrovent and Encephalopathy - a phase IV clinical study of FDA data

Summary:

Encephalopathy is reported as a side effect among people who take Atrovent (ipratropium bromide), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Levaquin, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Encephalopathy when taking Atrovent. It is created by eHealthMe based on reports of 33,026 people who have side effects when taking Atrovent from the FDA, and is updated regularly.

What is Atrovent?

Atrovent has active ingredients of ipratropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 33,210 Atrovent users. Check the latest studies of Atrovent.

What is Encephalopathy?

Encephalopathy (functioning of the brain is affected by some agent or condition) is found to be associated with 1,459 drugs and 1,608 conditions by eHealthMe. Check the latest studies of Encephalopathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

33,026 people reported to have side effects when taking Atrovent.
Among them, 112 people (0.34%) have Encephalopathy.

Among these 112 people:

* Approximation only. Some reports may have incomplete information.

Do you take Atrovent and have Encephalopathy?

- Check whether Encephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Atrovent:

Atrovent (33,210 reports)

Encephalopathy treatments and more:

Encephalopathy (27,832 reports)

How severe was Encephalopathy and when was it recovered:

Encephalopathy in Atrovent

Expand to all the drugs that have ingredients of ipratropium bromide:

Encephalopathy and drugs with ingredients of ipratropium bromide (200 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Atrovent:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Encephalopathy:

Encephalopathy (1,459 drugs)

Browse all the conditions that are associated with Encephalopathy:

Encephalopathy (1,608 conditions)

Related publications that referenced our studies

Kapoor A, Kumar V, Beniwal S, Dutta S, Goyal S, Kumar HS, "Posterior reversible encephalopathy syndrome in non-Hodgkin's lymphoma: Not necessarily reversible!", Clinical Cancer Investigation Journal, 2015 Mar .
Kapoor A, Kumar V, Beniwal S, Dutta S, Goyal S, Kumar HS, "Posterior reversible encephalopathy syndrome in non-Hodgkin's lymphoma: Not necessarily reversible!", Clinical Cancer Investigation Journal, 2015 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on ipratropium bromide (the active ingredients of Atrovent) and Atrovent (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.